Gemcitabine-induced haemolytic uraemic syndrome in pancreatic adenocarcinoma.


Journal

BMJ case reports
ISSN: 1757-790X
Titre abrégé: BMJ Case Rep
Pays: England
ID NLM: 101526291

Informations de publication

Date de publication:
08 Apr 2019
Historique:
entrez: 10 4 2019
pubmed: 10 4 2019
medline: 3 8 2019
Statut: epublish

Résumé

A woman in her mid-70s with metastatic pancreatic adenocarcinoma presented with fatigue, nausea and bilateral leg swelling, 4 days after an intravenous gemcitabine infusion. Additional examination and laboratory tests showed mild hypertension, low haemoglobin, high lactate dehydrogenase, low platelet count and high serum creatinine. The patient was subsequently diagnosed with haemolytic uraemic syndrome (HUS), and gemcitabine administration was immediately ceased. The patient received a 5-day course of methylprednisolone, with a full recovery being made 10 days after diagnosis. Clinicians should be aware of the rare but serious complication of gemcitabine-induced HUS (GiHUS), as early diagnosis and management, which includes prompt discontinuation of gemcitabine, are crucial in promptly resolving this condition. This case report describes one treatment that can be used for the treatment of GiHUS, while briefly covering some other novel treatments that have been described in other studies.

Identifiants

pubmed: 30962211
pii: 12/4/e228363
doi: 10.1136/bcr-2018-228363
pmc: PMC6453349
pii:
doi:

Substances chimiques

Antimetabolites, Antineoplastic 0
Antineoplastic Agents, Phytogenic 0
Glucocorticoids 0
Deoxycytidine 0W860991D6
Paclitaxel P88XT4IS4D
Methylprednisolone X4W7ZR7023
Gemcitabine 0

Types de publication

Case Reports Journal Article

Langues

eng

Informations de copyright

© BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Am J Nephrol. 1999;19(5):590-3
pubmed: 10575189
Cancer. 1999 May 1;85(9):2023-32
pubmed: 10223245
Pathol Biol (Paris). 2015 Jun;63(3):136-43
pubmed: 25845294
JOP. 2005 Jul 08;6(4):369-74
pubmed: 16006690
Am J Kidney Dis. 1999 Mar;33(3):555-62
pubmed: 10070921
Oncologist. 2010;15(3):259-69
pubmed: 20203172
N Engl J Med. 2009 Oct 22;361(17):1676-87
pubmed: 19846853
Clin Nephrol. 2009 Feb;71(2):130-9
pubmed: 19203505
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140
Invest New Drugs. 1994;12(1):29-34
pubmed: 7960602
Nephrol Dial Transplant. 1999 Oct;14(10):2523-4
pubmed: 10528696
Cancer Chemother Pharmacol. 2009 Jun;64(1):177-81
pubmed: 19116715
Am J Case Rep. 2012;13:89-91
pubmed: 23569497
J Gastrointest Oncol. 2014 Feb;5(1):E30-3
pubmed: 24490050
Nihon Shokakibyo Gakkai Zasshi. 2010 Oct;107(10):1676-85
pubmed: 20938119
Orphanet J Rare Dis. 2011 Sep 08;6:60
pubmed: 21902819
Lancet Oncol. 2007 Jul;8(7):634-41
pubmed: 17613425
Ann Hematol. 2005 Feb;84(2):110-4
pubmed: 15340761
Ren Fail. 2009;31(8):743-4
pubmed: 19814643
Iran J Kidney Dis. 2013 Sep;7(5):340-5
pubmed: 24072143
Gut Liver. 2014 Jan;8(1):109-12
pubmed: 24516709
Clin Exp Nephrol. 2014 Feb;18(1):4-9
pubmed: 24343712
J Clin Gastroenterol. 2008 May-Jun;42(5):551-2
pubmed: 18344882
Pediatr Nephrol. 2011 Jan;26(1):41-57
pubmed: 20556434
J Chemother. 2014 Jun;26(3):169-72
pubmed: 24091354
World J Clin Cases. 2018 Oct 26;6(12):531-537
pubmed: 30397609
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
pubmed: 18287387
Pediatr Nephrol. 2009 Apr;24(4):687-96
pubmed: 18800230
Intern Med J. 2013 Nov;43(11):1240-2
pubmed: 24237646
Blood Transfus. 2008 Jul;6(3):127-35
pubmed: 18705236
Cancer Chemother Pharmacol. 2017 Jan;79(1):1-7
pubmed: 27497971
NDT Plus. 2011 Aug;4(4):260-3
pubmed: 25949498
Ann Hematol. 2008 Jun;87(6):495-6
pubmed: 18097666
J Bras Nefrol. 2010 Jul-Sep;32(3):303-15
pubmed: 21103695

Auteurs

Adarsh Das (A)

Faculty of Medicine, Dentistry and Health Sciences, The University of Western Australia, Perth, Western Australia, Australia.

Andrew Dean (A)

Department of Medical Oncology, Saint John of God Hospital Subiaco, Subiaco, Western Australia, Australia.

Tim Clay (T)

Department of Medical Oncology, Saint John of God Hospital Subiaco, Subiaco, Western Australia, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH